优化KRAS治疗非小细胞肺癌。

IF 22.1 1区医学 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Annual review of medicine Pub Date : 2025-09-24 DOI:10.1146/annurev-med-043024-115849

Jeong Uk Lim, Marcelo V Negrao, David S Hong

{"title":"优化KRAS治疗非小细胞肺癌。","authors":"Jeong Uk Lim, Marcelo V Negrao, David S Hong","doi":"10.1146/annurev-med-043024-115849","DOIUrl":null,"url":null,"abstract":"This review examines the evolving treatment landscape for KRAS-mutant non-small cell lung cancer (NSCLC), along with the significance of KRAS mutations. The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with KRAS-mutant NSCLC, overcoming the long-standing challenge of targeting KRAS. However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C KRAS mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of KRAS-mutant NSCLC patients.","PeriodicalId":8056,"journal":{"name":"Annual review of medicine","volume":" ","pages":""},"PeriodicalIF":22.1000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer.\",\"authors\":\"Jeong Uk Lim, Marcelo V Negrao, David S Hong\",\"doi\":\"10.1146/annurev-med-043024-115849\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This review examines the evolving treatment landscape for KRAS-mutant non-small cell lung cancer (NSCLC), along with the significance of KRAS mutations. The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with KRAS-mutant NSCLC, overcoming the long-standing challenge of targeting KRAS. However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C KRAS mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of KRAS-mutant NSCLC patients.\",\"PeriodicalId\":8056,\"journal\":{\"name\":\"Annual review of medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":22.1000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual review of medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1146/annurev-med-043024-115849\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual review of medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1146/annurev-med-043024-115849","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

本文综述了KRAS突变的非小细胞肺癌（NSCLC）的治疗前景，以及KRAS突变的意义。KRAS G12C抑制剂的开发，如sotorasib和adagrasib，已经改变了KRAS突变型NSCLC患者的治疗前景，克服了靶向KRAS的长期挑战。然而，获得性耐药仍然是一个主要障碍，同时需要对非g12c KRAS突变进行有效治疗。正在进行的新一代抑制剂和联合策略的研究旨在改善kras突变的非小细胞肺癌患者的临床结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Optimizing KRAS Therapeutics for Non-Small Cell Lung Cancer.

This review examines the evolving treatment landscape for KRAS-mutant non-small cell lung cancer (NSCLC), along with the significance of KRAS mutations. The development of KRAS G12C inhibitors, such as sotorasib and adagrasib, has changed the treatment landscape for patients with KRAS-mutant NSCLC, overcoming the long-standing challenge of targeting KRAS. However, acquired resistance remains a major hurdle, along with the need for effective therapies for non-G12C KRAS mutations. Ongoing research into next-generation inhibitors and combination strategies aim to improve the clinical outcomes of KRAS-mutant NSCLC patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annual review of medicine 医学-医学：内科

CiteScore

24.90

自引率

0.00%

发文量

期刊介绍： The Annual Review of Medicine, which has been published since 1950, focuses on important advancements in diverse areas of medicine. These include AIDS/HIV, cardiology, clinical pharmacology, dermatology, endocrinology/metabolism, gastroenterology, genetics, immunology, infectious disease, neurology, oncology/hematology, pediatrics, psychiatry, pulmonology, reproductive medicine, and surgery. The journal's current volume has transitioned from a gated access model to an open access model through the Annual Reviews' Subscribe to Open program. All articles published in the journal are now available under a CC BY license.